WO2012037498A3 - Peptides anti-héparane sulfate bloquant l'infection au virus herpès simplex in vivo - Google Patents

Peptides anti-héparane sulfate bloquant l'infection au virus herpès simplex in vivo Download PDF

Info

Publication number
WO2012037498A3
WO2012037498A3 PCT/US2011/052002 US2011052002W WO2012037498A3 WO 2012037498 A3 WO2012037498 A3 WO 2012037498A3 US 2011052002 W US2011052002 W US 2011052002W WO 2012037498 A3 WO2012037498 A3 WO 2012037498A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
herpesviral
heparan sulfate
vivo
herpes simplex
Prior art date
Application number
PCT/US2011/052002
Other languages
English (en)
Other versions
WO2012037498A2 (fr
Inventor
Deepak Shukla
Vaibhav Tiwari
Original Assignee
University Of Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Illinois filed Critical University Of Illinois
Priority to EP11826047.0A priority Critical patent/EP2616478A4/fr
Publication of WO2012037498A2 publication Critical patent/WO2012037498A2/fr
Publication of WO2012037498A3 publication Critical patent/WO2012037498A3/fr
Priority to US13/842,193 priority patent/US20130189784A1/en
Priority to US14/555,000 priority patent/US9464113B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0081—Reaction with amino acids, peptides, or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16411—Rhadinovirus, e.g. human herpesvirus 8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cette invention concerne des peptides anti-héparane sulfate et des méthodes utilisant ces peptides pour prévenir ou traiter les infections virales, notamment les infections à Herpès simplex de type α, β et γ, par exemple les infections à HSV-1, à CMV et à HHV-8 respectivement. Les peptides comprennent au moins 10 acides aminés de séquence XRXRXKXXRXRX et/ou XXRRRRXRRRXK, X représentant n'importe quel acide aminé, par exemple les peptides comprenant au moins 10 acides aminés de séquence LRSRTKIIRIRH et/ou au moins 10 acides aminés de séquence MPRRRRIRRRQK. Les peptides peuvent être couplés à un ou à plusieurs composés thérapeutiques pour générer des conjugués peptides-composé thérapeutique, le composé thérapeutique pouvant être un ou plusieurs des éléments suivants : analogue de nucléoside, oligosaccharide et petite molécule.
PCT/US2011/052002 2010-09-16 2011-09-16 Peptides anti-héparane sulfate bloquant l'infection au virus herpès simplex in vivo WO2012037498A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP11826047.0A EP2616478A4 (fr) 2010-09-16 2011-09-16 Peptides anti-héparane sulfate bloquant l'infection au virus herpès simplex in vivo
US13/842,193 US20130189784A1 (en) 2010-09-16 2013-03-15 Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo
US14/555,000 US9464113B2 (en) 2010-09-16 2014-11-26 Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38352010P 2010-09-16 2010-09-16
US61/383,520 2010-09-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/842,193 Continuation-In-Part US20130189784A1 (en) 2010-09-16 2013-03-15 Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo

Publications (2)

Publication Number Publication Date
WO2012037498A2 WO2012037498A2 (fr) 2012-03-22
WO2012037498A3 true WO2012037498A3 (fr) 2012-07-05

Family

ID=45832272

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/052002 WO2012037498A2 (fr) 2010-09-16 2011-09-16 Peptides anti-héparane sulfate bloquant l'infection au virus herpès simplex in vivo

Country Status (2)

Country Link
EP (1) EP2616478A4 (fr)
WO (1) WO2012037498A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150158956A1 (en) * 2013-10-18 2015-06-11 The Charles Stark Draper Laboratory, Inc. Multivalent antiviral compositions, methods of making, and uses thereof
CN103788232A (zh) * 2013-12-23 2014-05-14 深圳市海普瑞药业股份有限公司 一种硫酸乙酰肝素十糖及其制备方法和应用
US9683017B2 (en) 2014-07-17 2017-06-20 University Tennessee Research Foundation Inhibitory peptides of viral infection
EP3186273A4 (fr) 2014-08-26 2018-05-02 University of Tennessee Research Foundation Immunothérapie de ciblage de l'amyloïdose
US10702572B2 (en) * 2015-07-28 2020-07-07 Carnegie Mellon University Methods and compounds to suppress viral genome release and packaging

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166173A (en) * 1991-01-29 1992-11-24 Genelabs Incorporated Method of treating herpes simplex virus infection
US20020119165A1 (en) * 1998-08-18 2002-08-29 Lambris John D. Peptides for inhibition of herpes simplex virus entry
US20060051368A1 (en) * 2004-07-23 2006-03-09 Northwestern University Herpes simplex virus mutations
US20090068215A1 (en) * 2007-07-05 2009-03-12 David Davido Herpes simplex virus mutant icp0 protein

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166173A (en) * 1991-01-29 1992-11-24 Genelabs Incorporated Method of treating herpes simplex virus infection
US20020119165A1 (en) * 1998-08-18 2002-08-29 Lambris John D. Peptides for inhibition of herpes simplex virus entry
US20060051368A1 (en) * 2004-07-23 2006-03-09 Northwestern University Herpes simplex virus mutations
US20090068215A1 (en) * 2007-07-05 2009-03-12 David Davido Herpes simplex virus mutant icp0 protein

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP2616478A4 *
TIWARI, V. ET AL.: "Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo", J. BIOL. CHEM., vol. 286, no. 28, 15 July 2011 (2011-07-15), pages 25406 - 25415, XP055106690 *

Also Published As

Publication number Publication date
EP2616478A2 (fr) 2013-07-24
EP2616478A4 (fr) 2014-04-23
WO2012037498A2 (fr) 2012-03-22

Similar Documents

Publication Publication Date Title
WO2012142093A3 (fr) Dérivés nucléosides à substitution 2'-cyano et leurs procédés d'utilisation pour traitement de maladies virales
TN2013000421A1 (en) 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2015149944A3 (fr) Complexe cargo de support polymère à utiliser comme agent immunostimulant ou comme adjuvant
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
WO2010081082A3 (fr) Dérivés de phosphoramidate de composés guanosine nucléoside pour le traitement d'infections virales
MX2022013596A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
WO2009129470A3 (fr) Méthodes de traitement d'infections dues au virus de l'herpès
WO2009024585A3 (fr) Composés d'imidazopyrazine
WO2012125926A3 (fr) Dérivés tétracycliques de xanthène et leurs méthodes d'utilisation en vue du traitement de maladies virales
AU2012358805A8 (en) Pyrazolo[1,5-a]pyrimidines as antiviral agents
WO2010029302A3 (fr) Composés pour traiter des infections virales
WO2012037498A3 (fr) Peptides anti-héparane sulfate bloquant l'infection au virus herpès simplex in vivo
WO2012018534A3 (fr) Composés de biphénylène substitué et procédés d'utilisation desdits composés pour le traitement de maladies virales
WO2008100447A3 (fr) Analogues nucléosidiques pour traitement antiviral
WO2010084115A3 (fr) Agents antiviraux
EP3418386A3 (fr) Compositions et méthodes permettant d'inhiber l'expression d'un gène du virus de l'hépatite b
WO2014205317A3 (fr) Peptides cycliques utilisés en tant qu'agents de ciblage de protéines
NZ702744A (en) D-amino acid compounds for liver disease
NZ604716A (en) 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
CA2753382C (fr) Inhibiteurs du virus de l'hepatite c
MX2012015292A (es) Pirazolo[1, 5]pirimidinas en la forma de agentes antivirales.
WO2009123776A3 (fr) Médicaments antiviraux pour le traitement d'une infection par un arénavirus
IN2014MN01547A (fr)
MX2010002557A (es) Interferon alfa 2b modificado por glicol de polietileno, la preparacion y el uso del mismo.
WO2011160024A3 (fr) Composés utiles en tant qu'agents antiviraux, compositions, et procédés d'utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11826047

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2011826047

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011826047

Country of ref document: EP